產(chǎn)品名稱(chēng)：C-Peptide ELISA
產(chǎn)    地：Demeditec 
產(chǎn)品貨號(hào)：DE1293
產(chǎn)品規(guī)格：96 Tests
產(chǎn)品說(shuō)明：
Special remarks: This product has been 510(k) cleared by the FDA/USA.
Insulin is synthesized in the pancreatic beta cells as a 6000 MW component of an 86 amino acid polypeptide called proinsulin. Proinsulin is subsequently cleaved enzymatically, releasing insulin into the circulation along with a residual 3000 MW fragment called connection ("C") peptide, so-named because it connects A and B chains of insulin within the proinsulin molecule. Human C-Peptide, a 31 amino acid residue peptide, has a molecular mass of approximately 3000 daltons. C-Peptide has no metabolic function. However, since C-Peptide and insulin are secreted in equimolar amounts, the immunoassay of C?Peptide permits the quantitation of insulin secretion. This is the reason for the clinical interest of serum and urinary determinations of C-Peptide. Moreover, C-Peptide measurement has several advantages over immunoassays of insulin.
The half-life of C-Peptide in the circulation is between two and five times longer than that of insulin. Therefore, C-Peptide levels are a more stable indicator of insulin secretion than the more rapidly changing levels of insulin. A very clear practical advantage of C-Peptide measurement arising from its relative metabolic inertness as compared to insulin is that C-Peptide levels in peripheral venous blood are about 5-6 times greater than insulin levels. Also, relative to an insulin assay, the C-Peptide assay's advantage is its ability to distinguish endogenous from injected insulin.
Thus, low C-Peptide levels are to be expected when insulin is diminished (as in insulin-dependent diabetes) or suppressed (as a normal response to exogenous insulin), whereas elevated C-Peptide levels may result from the increased β-cell activity observed in insulinomas.
C-Peptide has also been measured as an additional means for evaluating glucose tolerance and glibenclamide glucose tests.
C-Peptide levels are in many ways a better measurement of endogenous insulin secretion than peripheral insulin levels. C-Peptide may be measured in either blood or urine. With improved sensitive C-Peptide immunoassays, it is now possible to measure C-Peptide values at extremely low levels. The clinical indications for C-Peptide measurement include diagnosis of insulinoma and differentation from factitious hypoglycemia, follow-up of pancreatectomy, and evaluation of viability of islet cell transplants. Recently, these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus.
Clinical Indications for the DEMEDITEC C-Peptide ELISA
Assessment of residual ß-cell function in diabetics under insulin therapy
Detection and monitoring of the remission phase of type I diabetes
Adjunct in the differential diagnosis between type I (insulin dependent) and type II (non-insulin-dependent) diabetes
Diagnosis of insulin-induced factitious hypoglycemia.
Contribution to the diagnosis of insulinoma (insulin suppression test)
Prognostic index of fetal outcome in pregnant diabetic women
Evaluation of insulin secretion in liver disease
Monitoring of pancreasectomy
上海玉博生物技術(shù)有限公司在為生命科學(xué)領(lǐng)域提供豐富的產(chǎn)品與信息資源方面處于國(guó)內(nèi)**地位，公司提供的產(chǎn)品涵蓋了二十多個(gè)國(guó)家近五十萬(wàn)種產(chǎn)品，而且產(chǎn)品的數(shù)量與信息在不斷的增長(zhǎng)和更新，公司提供的產(chǎn)品能夠使生命科學(xué)工作者加快對(duì)生物化學(xué)，分子生物學(xué)，細(xì)胞生物學(xué)以及蛋白質(zhì)組學(xué)研究的認(rèn)知，以及分子診斷和臨床醫(yī)學(xué)領(lǐng)域的應(yīng)用。

產(chǎn)品留言

標(biāo)題

聯(lián)系人

聯(lián)系電話

內(nèi)容

驗(yàn)證碼

點(diǎn)擊換一張

注：1.可以使用快捷鍵Alt+S或Ctrl+Enter發(fā)送信息!
2.如有必要,請(qǐng)您留下您的詳細(xì)聯(lián)系方式!